Grey Matters Health Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher Joseph Moreau
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 601 West Broadway Vancouver BC Canada V5Z 4C2
- IPO Date
- Feb 1, 2016
- Website
- algernonpharmaceuticals.com
- Similar Companies
- Business
- Grey Matters Health Inc. is a clinical stage pharmaceutical development company focused on advancing therapies for liver disease, non-alcoholic steatohepatitis, chronic kidney disease, and stroke programs. The company operates in Canada and Australia, advancing a pipeline that includes repirinast for chronic kidney disease and N,N-Dimethyltryptamine for treatment of strokes and traumatic brain injuries, with additional research programs in related hepatology and neurology indications. Founded in 2015, it is headquartered in Frankfurt am Main, Hesse, Germany, and trades on the Canadian Securities Exchange under the GREY ticker. Core products and services include: discovery and preclinical to clinical development of therapeutic drug candidates; formulation and pharmacology studies; regulatory strategy and investor relations support for clinical-stage products; GMP-compliant manufacturing partnerships for translational and early-stage clinical materials; and strategic collaboration management with research institutions and contract development and manufacturing organizations (CDMOs). The company’s primary business activities center on identifying, validating, and advancing drug candidates through early-phase trials, with an emphasis on therapies addressing chronic kidney disease, liver disease, and acute neurological injuries. Latest major changes include: formation of strategic alliances and collaborations with research partners to accelerate pipeline candidates into clinical evaluation; execution of financing activities and potential equity transactions to support continued clinical development; updates to its corporate branding and corporate information under the GREY ticker; and organizational refinements to align operations across Canada and Australia for streamlined trial execution and regulatory submissions. The company also undergoes ongoing exploration of potential acquisitions or partnerships to broaden its development portfolio and strengthen its clinical development capabilities, with a view toward expanding its geographic footprint and capitalizing on emerging opportunities in hepatology and neurology therapeutic spaces. Subsidiary and parent relationships are aligned through a public listing on the CNSX/CSE and related cross-listings, enabling broader access to capital and strategic collaborations. Industry and business segments encompass pharmaceutical development services, translational research, and early-stage clinical development within biotechnology. Target markets include institutional investors, research partners, and potential licensing or collaboration partners seeking early-stage oncology-adjacent and neurology-focused therapeutic candidates, with geographic emphasis on Canada and Australia and academic hospital collaborations. Founding year is 2015, with headquarters in Frankfurt am Main, Germany, and additional corporate activities anchored in Canada and Australia to support clinical-stage drug development programs. The company maintains a network of CDMOs and contract research organizations (CROs) to support its clinical programs and potential future commercialization efforts.
Company News
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ Location
Dow leads Wall Street lower as bond yields rise and oil extends rally
Grey Matters Announces CAD $800K of Private Placement Equity Financing and Convertible Debentures
Grey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in Florida
Moderna shares soar as mRNA cancer vaccine succeeds in late-stage trial
Lindian Resources says Kangankunde licence remains valid as Malawi Government rejects illegal mining claims
Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.
Jeff Bezos's Blue Origin reaches for starts with $10bn funding round at a $130bn valuation
Deutsche Bank sees limited evidence AI is driving broad US job losses
Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida
Grey Matters Announces Increase to Private Placement Financing to $1.25 Million and Closing of Offering
Grey Matters Closes First Tranche of $500,000 of its Private Placement Financing
Grey Matters Improves Warrant Terms of Private Placement
Grey Matters Improves Warrant Terms of Private Placement
Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer's Clinical Trial at 2nd NovaScan Location Planned for Tampa
Grey Matters Announces Private Placement
Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation
Algernon Health announces effective date of name change to Grey Health Matters
Algernon Health to rebrand as Grey Matters Health, sharpen focus on Alzheimer's diagnostics